AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
205.10
0.00 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close205.10
Open205.66
Bid204.84 x 1200
Ask206.50 x 2200
Day's Range204.17 - 206.62
52 Week Range163.31 - 206.62
Volume3,151,240
Avg. Volume2,457,109
Market Cap132.755B
Beta1.61
PE Ratio (TTM)61.44
EPS (TTM)3.34
Earnings DateOct 23, 2018 - Oct 29, 2018
Forward Dividend & Yield5.28 (2.63%)
Ex-Dividend Date2018-08-16
1y Target Est204.26
Trade prices are not sourced from all markets
  • The Wall Street Journal15 hours ago

    U.S. Probes Drugmakers Over Free Services

    Federal prosecutors are probing whether big drugmakers including Sanofi, Gilead Sciences and Biogen potentially violated laws by providing free services to doctors and patients.

  • The 7 Best Biotech Stocks for Investors Who Hate Risk
    Kiplinger2 days ago

    The 7 Best Biotech Stocks for Investors Who Hate Risk

    Most of the buy-and-hold crowd tends to steer clear of biotech stocks, and for good reason. Biotechnology companies can be uncomfortably risky. Far too many horror stories of failed drug trials or the expiration of a crucial patent leading to massive stock plunges have circulated for years now, souring would-be buyers on the entire industry. However, conclusions based on a handful of biotech stocks may have erroneously prevented investors from plugging into a perfectly reasonable risk-reward relationship. Said differently: Not all biotech stocks turn into disasters. The industry as a group is up nearly 70% for the past five years, proving many of these companies can reward patient shareholders who choose wisely. It's simply a matter of doing your homework and having a little common sense. Here are seven biotech stocks that aren't nearly as risky as their typical peer. Thus, they may have a place in more risk-averse portfolios than most investors might presume. SEE ALSO: The 25 Best Stocks to Buy (According to Hedge Funds)

  • PR Newswire2 days ago

    Amgen And Los Angeles County Announce Collaboration To Support Life Science Innovation Hub - BioLA

    THOUSAND OAKS, Calif. and LOS ANGELES, Sept. 20, 2018 /PRNewswire/ -- Amgen (AMGN) and the County of Los Angeles today announced that Amgen has agreed to become a founding sponsor of BioLA, a newly formed organization focused on advancing a life science innovation hub in Los Angeles County. The innovation hub is designed to contribute to advancements in global health by strengthening the County's life sciences ecosystem and accelerating the pace of startup activity.

  • See what the IHS Markit Score report has to say about Amgen Inc.
    Markit2 days ago

    See what the IHS Markit Score report has to say about Amgen Inc.

    Amgen Inc NASDAQ/NGS:AMGN

  • AbbVie Faces California Insurance Department Suit for Humira
    Zacks3 days ago

    AbbVie Faces California Insurance Department Suit for Humira

    AbbVie's (ABBV) shares fall on a lawsuit by California insurance department accusing it of giving illegal kickbacks to doctors for prescribing Humira.

  • Does Ajovy's Approval Make Teva a Pain-Free Stock to Buy?
    Motley Fool4 days ago

    Does Ajovy's Approval Make Teva a Pain-Free Stock to Buy?

    Let's see if a new migraine prevention drug can help return to growth.

  • The Zacks Analyst Blog Highlights: UnitedHealth, Adobe, Amgen, UPS and Bayer
    Zacks4 days ago

    The Zacks Analyst Blog Highlights: UnitedHealth, Adobe, Amgen, UPS and Bayer

    The Zacks Analyst Blog Highlights: UnitedHealth, Adobe, Amgen, UPS and Bayer

  • 3 High-Quality Biotech Companies for 4th Quarter
    GuruFocus.com5 days ago

    3 High-Quality Biotech Companies for 4th Quarter

    On Monday, GuruFocus' High Quality Screener listed three biotechnology companies that offer good potential ahead of the fourth quarter: Biogen Inc. (BIIB), Gilead Sciences Inc. (GILD) and Novo Nordisk A/S (NVO). Warning! GuruFocus has detected 4 Warning Signs with ORCL. Berkshire Hathaway Inc. (BRK-A)(BRK-B) CEO Warren Buffett (Trades, Portfolio) has stressed several times that key investing criteria include predictable earnings and strong economic moat.

  • World's Largest Alzheimer's Survey Reveals Most Adults Believe a Cure Will be Developed in Their Lifetime
    PR Newswire5 days ago

    World's Largest Alzheimer's Survey Reveals Most Adults Believe a Cure Will be Developed in Their Lifetime

    THOUSAND OAKS, Calif., Sept. 17, 2018 /PRNewswire/ -- Amgen (AMGN), Novartis and Banner Alzheimer's Institute (BAI), in association with Alzheimer's Disease International (ADI), today announced results from the largest global survey to date investigating perceptions of Alzheimer's disease. Findings show that most adults (62 percent) are worried they may develop Alzheimer's, while nearly the same proportion believe it is likely a cure will be developed in their lifetime (60 percent).1 This World Alzheimer's Month, Amgen, Novartis, BAI and ADI are raising awareness about how volunteers can take part in clinical studies to benefit Alzheimer's research, potentially themselves and future generations.

  • Analysts Raise Ratings on Teva Stock on Ajovy’s FDA Approval
    Market Realist5 days ago

    Analysts Raise Ratings on Teva Stock on Ajovy’s FDA Approval

    On September 14, Teva Pharmaceutical Industries (TEVA) announced the FDA approval of Ajovy (fremanezumab), its injectable migraine drug. Following the news, a number of analysts raised their recommendations and target prices on Teva Pharmaceutical Industries.

  • Competition Dynamics for Ajovy—Teva’s Migraine Drug
    Market Realist5 days ago

    Competition Dynamics for Ajovy—Teva’s Migraine Drug

    Teva Pharmaceutical Industries (TEVA) received FDA approval for its Ajovy (fremanezumab-vfrm) injectable on September 14. The chart below shows the company’s quarterly sales trend. The marketing application for Ajovy was filed by Teva in Europe in February. Teva’s (TEVA) Ajovy is an anti-CGRP (calcitonin gene-related peptide) migraine prevention treatment and offers monthly and quarterly dosage options.

  • Top Research Reports for UnitedHealth, Adobe & Amgen
    Zacks5 days ago

    Top Research Reports for UnitedHealth, Adobe & Amgen

    Top Research Reports for UnitedHealth, Adobe & Amgen

  • Teva Pharmaceutical Up on Long-Awaited Migraine Drug Approval
    Market Realist5 days ago

    Teva Pharmaceutical Up on Long-Awaited Migraine Drug Approval

    On September 14, Teva Pharmaceutical Industries (TEVA) announced that the FDA had approved fremanezumab, its long-awaited migraine drug. The FDA had delayed the approval for the drug, which had been expected in June, due to a warning letter to Teva’s manufacturing partner Celltrion. The FDA provided a PDUFA (Prescription Drug User Fee Act) date of September 16.

  • TheStreet.com5 days ago

    Teva Shares Pop as FDA Approves Its Migraine Drug

    American depository receipts jumped in morning trading on Monday, Sept. 17, following the news late Friday that the company had clinched the U.S. Food and Drug Administration's nod for its migraine drug. It is the second anti-calcitonin gene-related peptide (CGRP) drug approved by the agency to prevent migraines, after Amgen Inc. CGRP is thought to play a key role in causing migraine headaches.

  • MarketWatch5 days ago

    Teva stock surges 7% after FDA approves migraine medication

    Teva Pharmaceutical Industries Ltd. shares surged nearly 7% in Monday premarket trade after the company's migraine therapy, intended to prevent chronic attacks of head pain along with other severe, disabling symptoms, was approved by the U.S. Food and Drug Administration. The therapy, Ajovy, is administered as an injection, using a prefilled syringe, and can be dosed on a quarterly or monthly basis. The monthly dose will cost $575 per dose and the quarterly dose will cost $1,725, Teva said, meaning the product's total yearly cost will be about $6,900 per year irrespective of dose. The pricing figures released by Teva refer to the therapy's wholesale acquisition cost, or the price a drugmaker offers wholesalers, from which discounts are typically taken. About 38 million Americans, or 12% of the population, experience migraines, and though the treatment landscape has been sparse so far, it is poised to become increasingly competitive. Another preventative therapy, from Amgen Inc. and Novartis AG [S: nvs] was approved by the FDA in May, and the companies cited the same price tag, or $6,900. A FDA decision for another drug in this class, from Eli Lilly & Co. , is expected in the near future as well. For the beleaguered Teva, the new approval is a "clear positive," said J.P. Morgan analyst Chris Schott, though he noted "the highly competitive dynamics in the space with Amgen, Teva and Lilly all launching within six months of each other and with relatively limited differentiation among agents." Schott expects Teva's migraine therapy could sell about $150 million next year and as much as $600 million by 2022; even so, he sees "few growth drivers or pipeline assets beyond Ajovy" given generic competition for the company's flagship multiple sclerosis medication and challenging conditions for generic drugs. Shares of the U.S.-listed Teva have surged 20.6% year-to-date, while the S&P 500 has risen 8.7% and the Dow Jones Industrial Average has lifted 5.8%.

  • Teva Analysts Say Migraine Drug Approval Gives Needed Relief
    Bloomberg5 days ago

    Teva Analysts Say Migraine Drug Approval Gives Needed Relief

    Teva Pharmaceutical Industries Ltd. climbed as much as 7.4 percent in early U.S. trading after FDA approval of its migraine drug, Ajovy, surprised the Street. The medicine is the second of its kind, behind Amgen’s Aimovig, and has the potential to reach sales of $1 billion in four years, according to BTIG analyst Timothy Chiang. “Teva continues to move in the right direction, now run by strong management, which is implementing deep cost reductions.

  • Is Now a Good Time to Buy Amgen?
    Motley Fool7 days ago

    Is Now a Good Time to Buy Amgen?

    Amgen's shares are rallying, but there are some risks that every investor ought to consider.

  • See what the IHS Markit Score report has to say about Amgen Inc.
    Markit7 days ago

    See what the IHS Markit Score report has to say about Amgen Inc.

    Amgen Inc NASDAQ/NGS:AMGN

  • Why bluebird and Celgene Should Worry About Amgen's Latest Clinical Victory
    Motley Fool8 days ago

    Why bluebird and Celgene Should Worry About Amgen's Latest Clinical Victory

    Cellular cancer therapies are a tough sell that could get a lot tougher.

  • Is Amgen (AMGN) a Great Stock for Value Investors?
    Zacks8 days ago

    Is Amgen (AMGN) a Great Stock for Value Investors?

    Let's see if Amgen (AMGN) stock is a good choice for value-oriented investors right now from multiple angles.

  • Analyzing Regenxbio’s Valuation Metrics
    Market Realist9 days ago

    Analyzing Regenxbio’s Valuation Metrics

    Regenxbio (RGNX) generated revenues, chiefly from licensing, of $40.03 million in the second quarter compared to $6.56 million in Q2 2017. For fiscal 2018, Regenxbio is expected to generate revenues of $194.55 million compared to $10.39 million in fiscal 2017. The increase in revenues helped Regenxbio generate a net income of $10.59 million in the second quarter compared to a net loss of $14.47 million in the second quarter of 2017.

  • Why Amgen Will Likely Be a Boring Dividend Stock Over the Next Few Years
    Motley Fool9 days ago

    Why Amgen Will Likely Be a Boring Dividend Stock Over the Next Few Years

    This big biotech might look more like a big pharma with sluggish growth but great dividends -- at least temporarily.

  • InvestorPlace10 days ago

    The Outlook for AstraZeneca Is Positive, But It’s Too Early to Pull the Trigger

    AstraZeneca’s (NYSE:AZN) profits look poised to resume growing, as a number of the drug company’s new treatments are expected to be approved by regulators. While ultimately the new drugs should compensate for the lost Crestor sales, it’s too early to say when the positive outlook will be reflected in AZN stock. If these forecasts hold, and AZN stock can trade consistently above $40 per share, AstraZeneca stock could finally rally.

  • PR Newswire11 days ago

    Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference

    THOUSAND OAKS, Calif. , Sept. 11, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9 a.m. GMT on Friday, Sept. 14, 2018 , in London ...

  • Merck's Keytruda Combo Gets Nod for Lung Cancer in Europe
    Zacks11 days ago

    Merck's Keytruda Combo Gets Nod for Lung Cancer in Europe

    Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting.